Nasdaq:US$17.92 (-0.64) | HKEX:HK$28.60 (-0.75) | AIM:£2.79 (-0.11)
News & Presentations
Previous Article   |   Next Article
Announcements & Press Releases, Regulatory Notice | 22 Apr 2015

Director’s Shareholding

London: Wednesday, 22 April 2015: Chi-Med received notification on 22 April 2015 that Mr Christopher Nash, Independent Non-executive Director, has purchased 1,388 ordinary shares of US$1.00 each in Chi-Med (the “Shares”) at a price of GBP18.00 per share on 21 April 2015. Following this purchase, Mr Nash is beneficially interested in 31,930 Shares, representing approximately 0.06% of the current issued share capital of Chi-Med.



Telephone: +852 2121 8200
Christian Hogg, CEO

Panmure Gordon (UK) Limited
Telephone: +44 20 7886 2500
Richard Gray
Andrew Potts

Citigate Dewe Rogerson
Telephone: +44 20 7638 9571
Anthony Carlisle Mobile: +44 7973 611 888
David Dible Mobile: +44 7967 566 919

About Chi-Med
Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products. Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases. Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China. Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.

Chi-Med is majority owned by the multinational conglomerate Hutchison Whampoa Limited (SEHK:13). For more information, please visit: